InterSectors: Legal perspectives on global business

The episode contains a handful of genuinely useful data points - invalidation rate comparisons across administrations, patent volume statistics, and a concise breakdown of three specific reform bills - but these are interspersed with substantial hedging ('remains to be seen,' 'we'll have to see') and broad observations that add little for an informed operator. The density is moderate, not high.

“During the first Trump administration, the invalidation rate...was around 51%. Under the Biden administration, that went up to 71%.”

“They issued 300,000 patents in 2024. There were 700,000 applications in 2024. And there's a backlog of 520,000 patents.”

The observation that large tech companies which originally benefited from strong IP now prefer weaker regimes (first-mover advantage argument) is the episode's most interesting framing. Otherwise the content is fairly standard legal briefing - recapping existing case law, bills, and policy trends - with no genuinely contrarian or first-principles argument sustained throughout.

“There's a tweet going around says, quote, delete all IP law.”

“It's interesting that as the companies were growing, and now with AI...they're taking somewhat opposite view.”

Both guests are senior IP litigation partners at a major international firm with real credentials - DOJ appellate background, work for Apple/Google/Amazon, and deep pharma litigation experience. However, this is a law firm hosting its own partners in what is essentially a firm marketing podcast, and neither guest is an operator who has built or run a business in this space.

“I grew up really at the Department of Justice in the Civil Appellate Branch. I've done over 50 appeals.”

“lead the practice in the high tech sector, doing work for companies like Apple and Google and Amazon and snap”

The episode earns points for named cases (Alice, Mayo), named legislation (PARA, PREVAIL, RESTORE), real figures ($2B Intel award, Fortress, 51% vs 71% invalidation rates, John Squires's 1,000-patent Honeywell portfolio, Goldman Sachs IP department), but the pharmaceutical supply chain and AI sections revert to abstraction, and the Anthropic CEO's 12-year disease-cure claim is passed on without sourcing or scrutiny.

“in 2017, there was a $2 billion award. It was against intel, and it was largely funded by a company called Fortress”

“He managed at Honeywell a portfolio of over 1,000 patents. He founded the IP department at Goldman Sachs.”

The host is a partner at the same firm as both guests, producing an inherently soft dynamic with no pushback, challenged assumptions, or productive disagreement. Questions are largely setup prompts ('can you give us some background'), and remarkable claims - like Anthropic CEO predicting disease eradication in 12 years - are met with applause rather than scrutiny.

“Those are some pretty astonishing statistics. Thanks for sharing, Mark.”

“So I assume tariffs would result in higher prices for consumers, generally speaking, but how would they impact your clients?”